Research ExplorerPublicationsBiomarkers for cetuximab-based neoadjuvant radiochemotherapy...

Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.

Standard

Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. / Grimminger, Peter P; Danenberg, Peter; Dellas, Kathrin; Arnold, Dirk; Rödel, Claus; Machiels, Jean-Pascal; Haustermans, Karin; Debucquoy, Annelies; Velenik, Vaneja; Sempoux, Christine; Bracko, Matej; Hölscher, Arnulf H; Semrau, Robert; Yang, Dongyun; Danenberg, Kathleen; Lenz, Heinz-Josef; Vallböhmer, Daniel.

In: CLIN CANCER RES, Vol. 17, No. 10, 10, 2011, p. 3469-3477.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Grimminger, PP, Danenberg, P, Dellas, K, Arnold, D, Rödel, C, Machiels, J-P, Haustermans, K, Debucquoy, A, Velenik, V, Sempoux, C, Bracko, M, Hölscher, AH, Semrau, R, Yang, D, Danenberg, K, Lenz, H-J & Vallböhmer, D 2011, 'Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.', CLIN CANCER RES, vol. 17, no. 10, 10, pp. 3469-3477. <http://www.ncbi.nlm.nih.gov/pubmed/21558395?dopt=Citation>

APA

Grimminger, P. P., Danenberg, P., Dellas, K., Arnold, D., Rödel, C., Machiels, J-P., Haustermans, K., Debucquoy, A., Velenik, V., Sempoux, C., Bracko, M., Hölscher, A. H., Semrau, R., Yang, D., Danenberg, K., Lenz, H-J., & Vallböhmer, D. (2011). Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. CLIN CANCER RES, 17(10), 3469-3477. [10]. http://www.ncbi.nlm.nih.gov/pubmed/21558395?dopt=Citation

Vancouver

Grimminger PP, Danenberg P, Dellas K, Arnold D, Rödel C, Machiels J-P et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. CLIN CANCER RES. 2011;17(10):3469-3477. 10.

Bibtex

@article{76f76455ece14add8fe8c824e2679b8f,
title = "Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.",
abstract = "Phase II trials in locally advanced rectal cancer have shown that cetuximab-based neoadjuvant radiochemotherapy is feasible but without an improvement in complete pathologic response rates. Our goal was to identify patients who would benefit from cetuximab-based neoadjuvant chemoradiation measuring gene expression levels of proteins involved in tumor growth [endothelial growth factor receptor (EGFR)], angiogenesis [VEGF, VEGF receptors 1 and 2 (VEGFR1, VEGFR2)], DNA repair [excision repair cross-complementing 1 (ERCC1)], and drug metabolism [thymidylate synthetase (TS)]. We also determined mutation status of KRAS and BRAF.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Combined Modality Therapy, Disease Progression, Clinical Trials, Phase II as Topic, Retrospective Studies, Neoadjuvant Therapy, Clinical Trials, Phase I as Topic, Antibodies, Monoclonal/adverse effects/*therapeutic use, Tumor Markers, Biological/analysis/*genetics, Antineoplastic Agents/adverse effects/therapeutic use, Biomarkers, Pharmacological/analysis/*metabolism, Carcinoma/*drug therapy/genetics/pathology/*radiotherapy, Gene Expression Regulation, Neoplastic/drug effects/radiation effects, Rectal Neoplasms/*drug therapy/genetics/pathology/*radiotherapy, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Combined Modality Therapy, Disease Progression, Clinical Trials, Phase II as Topic, Retrospective Studies, Neoadjuvant Therapy, Clinical Trials, Phase I as Topic, Antibodies, Monoclonal/adverse effects/*therapeutic use, Tumor Markers, Biological/analysis/*genetics, Antineoplastic Agents/adverse effects/therapeutic use, Biomarkers, Pharmacological/analysis/*metabolism, Carcinoma/*drug therapy/genetics/pathology/*radiotherapy, Gene Expression Regulation, Neoplastic/drug effects/radiation effects, Rectal Neoplasms/*drug therapy/genetics/pathology/*radiotherapy",
author = "Grimminger, {Peter P} and Peter Danenberg and Kathrin Dellas and Dirk Arnold and Claus R{\"o}del and Jean-Pascal Machiels and Karin Haustermans and Annelies Debucquoy and Vaneja Velenik and Christine Sempoux and Matej Bracko and H{\"o}lscher, {Arnulf H} and Robert Semrau and Dongyun Yang and Kathleen Danenberg and Heinz-Josef Lenz and Daniel Vallb{\"o}hmer",
year = "2011",
language = "English",
volume = "17",
pages = "3469--3477",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.

AU - Grimminger, Peter P

AU - Danenberg, Peter

AU - Dellas, Kathrin

AU - Arnold, Dirk

AU - Rödel, Claus

AU - Machiels, Jean-Pascal

AU - Haustermans, Karin

AU - Debucquoy, Annelies

AU - Velenik, Vaneja

AU - Sempoux, Christine

AU - Bracko, Matej

AU - Hölscher, Arnulf H

AU - Semrau, Robert

AU - Yang, Dongyun

AU - Danenberg, Kathleen

AU - Lenz, Heinz-Josef

AU - Vallböhmer, Daniel

PY - 2011

Y1 - 2011

N2 - Phase II trials in locally advanced rectal cancer have shown that cetuximab-based neoadjuvant radiochemotherapy is feasible but without an improvement in complete pathologic response rates. Our goal was to identify patients who would benefit from cetuximab-based neoadjuvant chemoradiation measuring gene expression levels of proteins involved in tumor growth [endothelial growth factor receptor (EGFR)], angiogenesis [VEGF, VEGF receptors 1 and 2 (VEGFR1, VEGFR2)], DNA repair [excision repair cross-complementing 1 (ERCC1)], and drug metabolism [thymidylate synthetase (TS)]. We also determined mutation status of KRAS and BRAF.

AB - Phase II trials in locally advanced rectal cancer have shown that cetuximab-based neoadjuvant radiochemotherapy is feasible but without an improvement in complete pathologic response rates. Our goal was to identify patients who would benefit from cetuximab-based neoadjuvant chemoradiation measuring gene expression levels of proteins involved in tumor growth [endothelial growth factor receptor (EGFR)], angiogenesis [VEGF, VEGF receptors 1 and 2 (VEGFR1, VEGFR2)], DNA repair [excision repair cross-complementing 1 (ERCC1)], and drug metabolism [thymidylate synthetase (TS)]. We also determined mutation status of KRAS and BRAF.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Combined Modality Therapy

KW - Disease Progression

KW - Clinical Trials, Phase II as Topic

KW - Retrospective Studies

KW - Neoadjuvant Therapy

KW - Clinical Trials, Phase I as Topic

KW - Antibodies, Monoclonal/adverse effects/therapeutic use

KW - Tumor Markers, Biological/analysis/genetics

KW - Antineoplastic Agents/adverse effects/therapeutic use

KW - Biomarkers, Pharmacological/analysis/metabolism

KW - Carcinoma/drug therapy/genetics/pathology/radiotherapy

KW - Gene Expression Regulation, Neoplastic/drug effects/radiation effects

KW - Rectal Neoplasms/drug therapy/genetics/pathology/radiotherapy

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Combined Modality Therapy

KW - Disease Progression

KW - Clinical Trials, Phase II as Topic

KW - Retrospective Studies

KW - Neoadjuvant Therapy

KW - Clinical Trials, Phase I as Topic

KW - Antibodies, Monoclonal/adverse effects/therapeutic use

KW - Tumor Markers, Biological/analysis/genetics

KW - Antineoplastic Agents/adverse effects/therapeutic use

KW - Biomarkers, Pharmacological/analysis/metabolism

KW - Carcinoma/drug therapy/genetics/pathology/radiotherapy

KW - Gene Expression Regulation, Neoplastic/drug effects/radiation effects

KW - Rectal Neoplasms/drug therapy/genetics/pathology/radiotherapy

M3 - SCORING: Journal article

VL - 17

SP - 3469

EP - 3477

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 10

M1 - 10

ER -